Financial reports
10-Q
2024 Q1
Quarterly report
15 May 24
10-K
2023 FY
Annual report
1 Apr 24
10-Q
2023 Q3
Quarterly report
14 Nov 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
ARS
2022 FY
Annual report to shareholders
30 Jun 23
10-Q
2023 Q1
Quarterly report
15 May 23
10-K
2022 FY
Annual report
31 Mar 23
10-Q
2022 Q3
Quarterly report
10 Nov 22
10-Q
2022 Q2
Quarterly report
15 Aug 22
10-Q
2022 Q1
Quarterly report
16 May 22
Current reports
8-K
Material Modifications to Rights of Security Holders
26 Jul 24
8-K
New name represents therapeutic focus on inhibiting TNF-alpha to regulate the immuno-metabolic system
26 Jul 24
8-K
Material Modifications to Rights of Security Holders
24 Jun 24
8-K/A
Entry into a Material Definitive Agreement
20 Jun 24
8-K
Entry into a Material Definitive Agreement
17 Jun 24
8-K
Material Modifications to Rights of Security Holders
23 May 24
8-K
MyMD Pharmaceuticals Secures Strategic Investments
21 May 24
8-K
Departure of Directors or Certain Officers
18 Apr 24
8-K
Entry into a Material Definitive Agreement
8 Apr 24
8-K/A
Amendments to Articles of Incorporation or Bylaws
26 Mar 24
Registration and prospectus
S-3
Shelf registration
21 Jun 24
D
$15.15 mm in equity / options / securities to be acquired, sold $15.15 mm, 5 investors
31 May 24
D
$26.85 mm in equity / options / securities to be acquired, sold $26.85 mm, 4 investors
31 May 24
424B5
Prospectus supplement for primary offering
23 Feb 23
D
$7.41M in options / securities to be acquired, 8 investors
30 Aug 22
424B5
Prospectus supplement for primary offering
17 Aug 22
S-8
Registration of securities for employees
5 Jul 22
424B3
Prospectus supplement
11 May 21
S-3/A
Shelf registration (amended)
28 Apr 21
425
Business combination disclosure
13 Apr 21
Proxies
DEF 14A
Definitive proxy
1 Jul 24
PRE 14A
Preliminary proxy
20 Jun 24
DEFA14A
Additional proxy soliciting materials
21 Jul 23
DEF 14A
Definitive proxy
30 Jun 23
PRE 14A
Preliminary proxy
20 Jun 23
DEFA14A
Additional proxy soliciting materials
22 Mar 23
DEF 14A
Definitive proxy
13 Mar 23
PRE 14A
Preliminary proxy
3 Mar 23
DEFA14A
Additional proxy soliciting materials
26 Oct 22
DEF 14A
Definitive proxy
26 Oct 22
Other
EFFECT
Notice of effectiveness
12 May 21
CORRESP
Correspondence with SEC
10 May 21
CORRESP
Correspondence with SEC
28 Apr 21
UPLOAD
Letter from SEC
16 Apr 21
EFFECT
Notice of effectiveness
24 Mar 21
CORRESP
Correspondence with SEC
19 Mar 21
UPLOAD
Letter from SEC
22 Jan 21
EFFECT
Notice of effectiveness
26 Aug 20
CORRESP
Correspondence with SEC
24 Aug 20
UPLOAD
Letter from SEC
21 Aug 20
Ownership
3
Stephen Friscia
28 Jun 24
3
Initial statement of insider ownership
30 May 24
SC 13D
PharmaCyte Biotech, Inc.
30 May 24
3
Mitchell Glass
16 May 24
SC 13G
Global X Management CO LLC
14 Feb 24
SC 13G/A
Iroquois Capital Management, LLC
14 Feb 24
4
Paul Rivard
24 Aug 23
4
Paul Rivard
18 Aug 23
4
Christopher C Chapman JR
9 Jun 23
4
Adam Kaplin
9 Jun 23